Company Information
USD
2.325
- (-3.1%)
NASDAQ:BNR, BURNING ROCK BIOTECH LIMITED
Industry: Diagnostics & Research
End of Day: 9 May 2025 GMT-4
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.
Address
No. 5, Xingdao Ring Road North
International Bio Island
Website
Classification
Sector
Healthcare
Industry Group
Medical Diagnostics & Research
Industry
Diagnostics & Research
Key Executives
Mr. Feng Deng
Director
Mr. Leo Li
CFO/Director
Ms. Wendy Hayes
Director
Mr. Yusheng Han
CEO/Chairman of the Board/Director/Founder
Dr. Shaokun Chuai
Chief Scientific Officer/Director
Mr. Gang Lu
Director
Dr. Min-Jui Shen
Director
Dr. Zhihong Zhang
Chief Technology Officer
Dr. Licen Lisa Xu
Director
Ownership
Institution Holdings
Kynam Capital Management, LP
8,694,426 (8.468%)
GIC Private Ltd
4,056,400 (3.951%)
MFS Investment Management KK
4,045,110 (3.940%)
Massachusetts Financial Services Company
4,045,110 (3.940%)
MFS Investment Management
3,702,920 (3.606%)
Fidelity International Ltd
2,808,981 (2.736%)
Millennium Management LLC
1,742,028 (1.697%)
Nikko Asset Management Co Ltd
730,679 (0.712%)
Nikko Asset Management Americas Inc
667,065 (0.650%)
Sumitomo Mitsui Trust Holdings Inc
667,065 (0.650%)
Funds Holdings
MFS® Emerging Markets Equity
3,412,368 (3.323%)
MFS® VIT II Emerging Markets Equity Port
18,474 (0.018%)
Make Smart Investment Choices